United Therapeutics (UTHR) Tops Q2 EPS by $1.07
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $494.63 -0.53%
Revenue Growth %: -1.2%
Financial Fact:
Selling, general and administrative: 100.1M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -1.2%
Financial Fact:
Selling, general and administrative: 100.1M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $4.09, $1.07 better than the analyst estimate of $3.02. Revenue for the quarter came in at $446.5 million versus the consensus estimate of $378.75 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Lumentum shares rise on analyst upgrades, AI demand outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
